{
    "organizations": [],
    "uuid": "b117307a46c086dd1ae7e63fe8a6531a22429b77",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abbvies-upadacitinib-granted-break/brief-abbvies-upadacitinib-granted-breakthrough-therapy-designation-from-fda-idUSASB0C03J",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie's Upadacitinib Granted Breakthrough Therapy Designation From FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Abbvie Inc:\n* ABBVIEâ€˜S UPADACITINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ATOPIC DERMATITIS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:13:00.000+02:00",
    "crawled": "2018-01-09T17:19:04.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "upadacitinib",
        "granted",
        "breakthrough",
        "therapy",
        "designation",
        "food",
        "drug",
        "administration",
        "atopic",
        "dermatitis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}